Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma

G. E. D'Alonzo, R. A. Nathan, S. Henochowicz, R. J. Morris, P. Ratner and S. I. Rennard
University of Texas Health Science Center, Houston.

OBJECTIVE--To compare the efficacy and safety of inhaled salmeterol xinafoate, a long-acting beta 2-adrenoceptor agonist, with that of albuterol, a short-acting inhaled beta 2-agonist, in the treatment of asthma. DESIGN--Randomized, double-blind, placebo-controlled, parallel-group study. SETTING--Eleven outpatient clinical centers. SUBJECTS--A total of 322 male and female patients at least 12 years of age with chronic symptomatic asthma requiring daily therapy. INTERVENTION--Patients were treated with salmeterol xinafoate (42 micrograms inhaled twice daily), albuterol (180 micrograms inhaled four times daily), or placebo (four times a day) for 12 weeks; patients in all three groups could use inhaled albuterol as backup medication for breakthrough symptoms. MAIN OUTCOME MEASURES--Serial 12-hour forced expiratory flow in 1 second (FEV1), peak expiratory flow (PEF), asthma symptoms, nocturnal awakenings due to asthma, episodes of asthma exacerbations, and electrocardiography. RESULTS--The mean area under the curve for FEV1 throughout each 12-hour period was consistently greater after a single dose of salmeterol than after two doses of albuterol administered 6 hours apart (P < .001), with the difference ranging from 3.1 to 4.3 L.h. Salmeterol produced an average increase in morning and evening PEF of 26 and 29 L/min, respectively, over pretreatment values compared with decreases of -13 and -3 L/min, respectively, in the albuterol group and -2 L/min both in the morning and evening in the placebo group (P < .001). Patients in the salmeterol group had significantly fewer days and nights with symptoms than did either the albuterol or placebo group (P < .001). Responses to salmeterol were similar at day 1 and at week 12. Adverse events in all treatment groups were equally infrequent, and no clinically significant change in cardiac rhythm was observed with salmeterol treatment. CONCLUSION--Salmeterol inhaled twice daily is more effective than albuterol inhaled four times a day (or as needed) in patients with asthma requiring maintenance therapy. No deterioration of asthma control was observed with the use of salmeterol over a 3-month period.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Meta-Analysis: Effect of Long-Acting {beta}-Agonists on Severe Asthma Exacerbations and Asthma-Related Deaths
Salpeter et al.
ANN INTERN MED 2006;144:904-912.
ABSTRACT | FULL TEXT  

beta-Adrenergic Receptor Polymorphisms and Response to Salmeterol
Wechsler et al.
Am. J. Respir. Crit. Care Med. 2006;173:519-526.
ABSTRACT | FULL TEXT  

Pharmacological Management to Reduce Exacerbations in Adults With Asthma: A Systematic Review and Meta-analysis
Sin et al.
JAMA 2004;292:367-376.
ABSTRACT | FULL TEXT  

Levalbuterol in the Treatment of Patients With Asthma and Chronic Obstructive Lung Disease
D'Alonzo
JAOA: Journal of the American Osteopathic Association 2004;104:288-293.
ABSTRACT | FULL TEXT  

{beta}-Agonist Intrinsic Efficacy: Measurement and Clinical Significance
Hanania et al.
Am. J. Respir. Crit. Care Med. 2002;165:1353-1358.
FULL TEXT  

Long-Acting {beta}2-Agonist Monotherapy vs Continued Therapy With Inhaled Corticosteroids in Patients With Persistent Asthma: A Randomized Controlled Trial
Lazarus et al.
JAMA 2001;285:2583-2593.
ABSTRACT | FULL TEXT  

Inhaled Corticosteroid Reduction and Elimination in Patients With Persistent Asthma Receiving Salmeterol: A Randomized Controlled Trial
Lemanske et al.
JAMA 2001;285:2594-2603.
ABSTRACT | FULL TEXT  

Therapeutic Options for Persistent Asthma
Holgate
JAMA 2001;285:2637-2639.
FULL TEXT  

Evidence-based guideline on the primary care management of asthma
Eccles et al.
Fam Pract 2001;18:223-229.
FULL TEXT  

Clinical Predictors of Health-related Quality of Life Depend on Asthma Severity
MOY et al.
Am. J. Respir. Crit. Care Med. 2001;163:924-929.
ABSTRACT | FULL TEXT  

Effectiveness and Safety of Salmeterol in Nonspecialist Practice Settings
D'Urzo et al.
Chest 2001;119:714-719.
ABSTRACT | FULL TEXT  

On demand use of {beta}2-agonists led to better asthma control than regular use in moderate to severe asthma
Quarton
Evid. Based Nurs. 2001;4:14-14.
FULL TEXT  

A Randomized, Placebo-Controlled Study To Evaluate the Role of Salmeterol in the In-Hospital Management of Asthma
Peters et al.
Chest 2000;118:313-320.
ABSTRACT | FULL TEXT  

Salmeterol Administration by Metered-Dose Inhaler Alone vs Metered-Dose Inhaler Plus Valved Holding Chamber
Demirkan et al.
Chest 2000;117:1314-1318.
ABSTRACT | FULL TEXT  

Combined Salmeterol 50 {micro}g and Fluticasone Propionate 250 {micro}g in the Diskus Device for the Treatment of Asthma
SHAPIRO et al.
Am. J. Respir. Crit. Care Med. 2000;161:527-534.
ABSTRACT | FULL TEXT  

Effect of Long-term Salmeterol Therapy Compared With As-Needed Albuterol Use on Airway Hyperresponsiveness
Rosenthal et al.
Chest 1999;116:595-602.
ABSTRACT | FULL TEXT  

Is {beta}-Adrenergic-Mediated Airway Relaxation of Salmeterol Antagonized by Its Solvent Xinafoic Acid?
Groeben and Emala
Chest 1999;115:1678-1683.
ABSTRACT | FULL TEXT  

Efficacy of Salmeterol Xinafoate in the Treatment of COPD
Mahler et al.
Chest 1999;115:957-965.
ABSTRACT | FULL TEXT  

Long-term Cardiovascular Safety of Salmeterol Powder Pharmacotherapy in Adolescent and Adult Patients With Chronic Persistent Asthma: A Randomized Clinical Trial
Chervinsky et al.
Chest 1999;115:642-648.
ABSTRACT | FULL TEXT  

Nocturnal Asthma: Effect of Salmeterol on Quality of Life and Clinical Outcomes
Lockey et al.
Chest 1999;115:666-673.
ABSTRACT | FULL TEXT  

Comparative Efficacy and Safety of Albuterol Sulfate Spiros Inhaler and Albuterol Metered-Dose Inhaler in Asthma
Nelson et al.
Chest 1999;115:329-335.
ABSTRACT | FULL TEXT  

Randomised placebo controlled trial of beta  agonist dose reduction in asthma
Harrison et al.
Thorax 1999;54:98-102.
ABSTRACT | FULL TEXT  

Asthma control during long term treatment with regular inhaled salbutamol and salmeterol
Taylor et al.
Thorax 1998;53:744-752.
ABSTRACT | FULL TEXT  

Treatment of Nocturnal Airway Obstruction Improves Daytime Cognitive Performance in Asthmatics
WEERSINK et al.
Am. J. Respir. Crit. Care Med. 1997;156:1144-1150.
ABSTRACT | FULL TEXT  

Using {beta}2-stimulants in asthma
DTB 1997;35:1-4.
ABSTRACT | FULL TEXT  

Ragweed Immunotherapy in Adult Asthma
Creticos et al.
NEJM 1996;334:501-507.
ABSTRACT | FULL TEXT  

{beta}-Adrenergic Bronchodilators
Nelson
NEJM 1995;333:499-507.
FULL TEXT  

A TWICE-DAILY BETA-AGONIST FOR ASTHMA
JWatch General 1994;1994:2-2.
FULL TEXT